1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis open and competitive grants program funds initiatives to improve health outcomes for people living with, or at risk of developing, chronic conditions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Unspecified, but aims to fund initiatives that improve health outcomes for people living with, or at risk of developing, chronic conditions. Confirm the full requirements in the official notice before applying.
Chronic Conditions Prevention and Integrated Care Grants Program is funded by Australian Government Department of Health, Disability and Ageing. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Causal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This funding opportunity invites applications for innovative research on the causal factors of human behaviors and the direct or downstream impacts of those behaviors on overall health and oral health among people with chronic conditions.
Small Business Program at NINR is sponsored by National Institute of Nursing Research (NINR) / NIH. The Small Business Program at NINR provides technical and financial support for small businesses to develop new and innovative products, technologies, and services that improve health. This can include technologies for managing chronic conditions, which aligns with lymphedema and chronic venous insufficiency.
ARPA-H selected 13 research teams for EVIDENT, a $139.4M initiative to develop objective clinical endpoints for rapid-acting behavioral health therapies including psilocybin. At least $50M will match state psychedelic research investments under a Trump executive order.
Read articleARPA-H's $139.4M EVIDENT initiative selects 13 research teams to build objective biomarkers for psilocybin, neuromodulation, and rapid-acting mental health therapies.
Read articleCDC-RFA-EH-27-0074 posted as a forecast September 22, 2026: 6 expected awards at $750,000 to $900,000. That is flat funding against the expiring cycle — and the only proven way in is the consortium model Arizona used to bring three states under one award.
Read article